Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GRM8 | O00222 | 3/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.33 |
| ▸ | GRM6 | O15303 | 2/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2596237 | 0.84 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPT | |
| SCHEMBL27897852 | 0.77 | GRM8 (0.34) | ALDH1A1SMN1; SMN2LMNAMAPTTP53 | |
| SCHEMBL27897851 | 0.77 | GRM8 (0.34) | ALDH1A1SMN1; SMN2LMNAMAPTTP53 | |
| SCHEMBL12184227 | 0.75 | KMT2A (0.39) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL14965493 | 0.75 | CHEK1 (0.39) | ALDH1A1SMN1; SMN2LMNAMAPTHPGD | |
| SCHEMBL27915325 | 0.74 | CHEK1 (0.42) | ALDH1A1SMN1; SMN2LMNAMAPTTP53 | |
| SCHEMBL2595550 | 0.74 | CHEK1 (0.42) | ALDH1A1SMN1; SMN2LMNAMAPTTP53 | |
| SCHEMBL2589883 | 0.74 | SNCA (0.42) | ALDH1A1SMN1; SMN2LMNAMAPTCTSD | |
| SCHEMBL2596244 | 0.72 | SNCA (0.40) | ALDH1A1SMN1; SMN2LMNAMAPTNPC1 | |
| SCHEMBL2595482 | 0.71 | SUV39H2 (0.42) | ALDH1A1SMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716287-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2014-05-06 | — | — | US | disclosed |
| EP-2569290-A2 | PHARMACEUTICAL COMPOUNDS | Sentinel Oncology Limited (GB) | 2013-03-20 | — | — | EP | disclosed |
| US-20130065900-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2013-03-14 | — | — | US | disclosed |
| WO-2011141716-A2 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065900-A1 | PHARMACEUTICAL COMPOUNDS | CSNK1A1, FRK, CSNK1E | ALDH1A1 3289/4885SMN1; SMN2 3053/4885LMNA 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.